22 July 2026

(does NOT get the FDA permitted list) T-1, and the evidence set is unchanged from yesterday's confirmed-stack update. The one thing worth doing on the eve was verifying the agenda mechanics, and they check out: per the [FDA calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) and trade coverage ([PeptideKnow](https://www.peptideknow.com/blog/fda-pcac-july-2026-bpc-157-tb-500-mots-c-semax-epitalon)), BPC-157 (free base + acetate) and KPV are voted Day 1 (July 23), with TB-500 and MOTS-c also on the July 23 slate — the separate five-peptide batch (including injectable GHK-Cu) is deferred to a meeting before end-Feb 2027. So the resolution basket is clean; no re-sequencing surprise. Overnight Firehose captured zero matches and no new regulatory evidence landed. [Forbes' Awan](https://www.forbes.com/sites/omerawan/2026/07/21/fdas-review-of-peptides-signals-a-growing-public-health-challenge--separating-science-from-hype/) published a "separating science from hype" piece July 21 reinforcing the establishment-safety frame. Staff-against-all-7 + the advisory-follows-staff base rate, set against a deliberately reconstituted override panel with advocate oral presentations still absent from the docket, net to the honest 0.70. Skeptic/Bayesian did not diverge. Not re-flagged (delta 0) — but still flagged for operator resolution after Wednesday's vote.

(≥2 of 4 Day-1 peptides get the permitted list) Same confirmed-stack evidence, same cap. A pro-peptide panel raises the odds ≥2 of {BPC-157, KPV, TB-500, MOTS-c} pass, but staff states human clinical evidence is absent for KPV, TB-500 and MOTS-c, [PSM](https://www.safemedicines.org/2026/07/five-reasons-bulk-peptides.html) flags TB-500 tumor-proliferation risk, and the basket requires two correlated overrides at once. Held at 0.38, internally consistent with BPC-157 (the weakest) sitting near 0.30 to pass. Flagged for operator resolution after the vote.

— Month 19+ post-facility-acquisition, no launch announcement. A confirmed pro-peptide panel is a mild Wednesday tailwind; a denial a mild delay risk. OneTwenty peptide ops 13+ weeks, launch-first/retreat-under-enforcement pattern intact. Q2 earnings in August is the next real catalyst. Horizon Dec 31. Holding.

— The Forbes July 21 "growing public health challenge" piece adds a fresh skeptical feature but is a contributor column, not a top-5 outlet (NYT/WSJ/CNN/NPR/WaPo). The FAERS BPC-157 contamination hospitalization, the Hangzhou Yiqi import alert, and independent testing (<50% labeled compound) remain citation-ready for a top-5 feature during the July 23–30 convergence week. None yet. 252 days out. Holding.

(fewer than 1M enrollees by Dec 31) — Day 22. No enrollment data, no operational failures, near-zero consumer search demand in GSC (a single "how to enroll" query at position 52). First pharmacy claims data expected late July. Physician-gated quiet ramp + year-one Part D base rates keep the sub-1M outcome dominant. Holding.

— First-party Katalys logged 1 conversion / $300 (Trim Rx) this week vs $2,049 prior, clicks +7%, GSC impressions −20% w/w — a soft revenue week reading as single-provider lumpiness, not a thesis change. Zero peptide DTC affiliates in the network; staff-against-all-7 further delays any compliant peptide affiliate surface. GLP-1 CPA dominance ($260–500 vs peptide $0) structural. Holding.